

ASX Announcement | 23 December 2020 Althea Group Holdings (ASX:AGH)

Supply and Distribution Agreement for UK and Jersey

Investment Highlights:

- Althea has entered an agreement with Lyphe Group for the supply and distribution of Althea products in the United Kingdom and Jersey
- Althea products will be distributed by Lyphe Group through The Medical Cannabis Clinics in the UK and Jersey and dispensed in the UK through Lyphe Group owned pharmacy, Dispensary Green
- The agreement is an important milestone in Althea's UK growth strategy, as the Company continues to increase patient numbers in the territory
- Lyphe Group is a UK provider of patient focused, reliable and seamless, medical cannabis care and medicine

23 December 2020: Australian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company') is pleased to announce that the Company has entered into an agreement with Lyphe Group Limited ('Lyphe Group') for the supply and distribution of Althea products ('Agreement') in the United Kingdom and Jersey.

Under the Agreement, Lyphe Group will have non-exclusive rights to distribute Althea's range of products in the United Kingdom, which will be available through The Medical Cannabis Clinics (**'TMCC'**) and dispensed through Lyphe Group owned pharmacy, Dispensary Green.

Lyphe Group has also established a new structure in Jersey to help serve the thousands of local patients in need of medical cannabis treatment, with Althea granting Lyphe Group exclusive distribution rights for Jersey.

The Agreement is for an initial term of 12 months, with the option to extend for further terms by agreement.

Commenting on the Agreement, Althea CEO, Josh Fegan, said: "The supply and distribution agreement with Lyphe Group is an important milestone in Althea's UK strategy, as the Company continues to increase its market share in the rapidly growing territory. The agreement with Lyphe Group creates supplementary growth for the Company, whilst further enhancing our brand awareness and standing in the marketplace. We look forward to the Althea brand continuing to have strong representation on Lyphe Group's formulary in the UK and Jersey."

Lyphe Group CEO, Dean Friday, said: "It's hard to believe that a few months ago none of the patients in Jersey were able to obtain critical medical cannabis treatments, instead they were driven to the black market. Now, not only does LYPHE Group have an operating clinic on the island, TMCC Jersey, it also has a fantastic pharmacy partner in Reid's Pharmacy chain. We are pleased that Althea has come onboard with us as we work to ensure every patient has a consistent and affordable supply of medical cannabis."

Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

E. info@althea.lifeP. 1300 70 20 20W. althea.life



-ENDS-

Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea Josh Fegan CEO & Managing Director M: 1300 70 20 20 E: contact@althea.life Media Enquiries Dan Francome Media Relations P: +613 9650 5096 E: <u>dfrancome@althea.life</u>

Investor Relations Jane Morgan Investor Relations Partner M: +61 405 555 618 E: jm@janemorganmanagement.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd (ASX:AGH) is a global pharmaceutical company and supplier of medicinal cannabis. Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia, the United Kingdom and Germany, with plans to expand the brand into emerging markets across the world.

To learn more, please visit: www.althea.life

Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

E. info@althea.lifeP. 1300 70 20 20W. althea.life

(O) @altheacompany